Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia by P. J. Hengeveld, J. Schilperoord-Vermeulen, M. Y. van der Klift, J. M. N. Dubois, P. M. Kolijn, F. G. Kavelaars, M. Rijken, J. A. Dobber, K. Nasserinejad, S. Kersting, P. E. Westerweel, A. P. Kater, A. W. Langerak, M-D. Levin

Get full text